Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Its the comprehensive semaglutide guide you need to read
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has revolutionized diabetes treatment due to its potent and sustained blood sugar-lowering effects
Even a couple of samples to research
These gastrointestinal side effects appear to be qualitatively similar to those reported in clinical studies of selective GLP-1 receptor agonists
It is the leading cause of irreversible blindness globally, with projections indicating it could affect over 100 million individuals by 2040 (74)
The most frequently reported adverse effects are gastrointestinal and typically occur during treatment initiation or dose escalation: Nausea (very common): Usually mild to moderate and diminishing over time Diarrhoea (very common): Potentially contributing to dehydration Vomiting (common): Particularly during early treatment phases Constipation (common): Due to delayed gastric emptying Abdominal pain and dyspepsia (common): May affect eating and drinking patterns Decreased appetite (very common): A therapeutic effect that may inadvertently reduce fluid intake Other notable side effects include: Injection site reactions (erythema, pruritus, swelling) Fatigue and dizziness, which may be exacerbated by dehydration Hypoglycaemia, particularly when used with insulin or sulfonylureas (doses of these medications may need to be reduced when starting tirzepatide) Increased heart rate (modest elevation of 2-4 beats per minute) Gallbladder problems including gallstones and inflammation Potential worsening of diabetic retinopathy in patients with pre-existing disease According to NICE guidance , patients should be counselled about these expected side effects before initiating treatment
